Stockholm, Sweden · Founded 2017 · Privately Held (backing)
Developer of therapeutic drugs designed to improve clinical outcomes in cardiac failure. AnaCardio is based in Stockholm, Sweden and was founded in 2017. It was valued at $293 million at its Series B in Sep 2026, the last priced event on record. It has raised $44.2 million across 1 recorded round; the latest was a Series B in Sep 2026.
PMV mark · valuation
$292.9M
Oct 2026
Priced at
its Series B
Sep 2026
Total raised
$44.2M
Last round
Series B
Sep 2026
Team — not yet on record
No current team members for AnaCardio are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of AnaCardio with a free account
·The post-money valuation on its round
·The complete investor list: 13 names
·Watch AnaCardio: the Monday email on marks, rounds and moves
